Dr. Podany, a second year Hematology-Oncology presented her abstract “Racial differences in genomic profiles and targeted treatment use in ER+ HER2- metastatic breast cancer“ at the 2024 ASCO Annual Meeting. She was chosen to be interviewed to discuss disparities in the use of PI3K inhibitors for Black patients with estrogen receptor–positive, HER2-negative metastatic breast cancer while other drugs that do not require genomic profiling were similarly used. You can view the interview here.
Emily Podany Interviewed by The ASCO Post
